Sheeba Koshy Thomas, M.D.

Peer-Reviewed Articles

1. Pasvolsky O, Saliba RM, Masood A, Mohamedi AH, Tanner MR, Bashir Q, Srour S, Saini N, Ramdial J, Nieto Y, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Impact of gender on outcomes of patients with multiple myeloma undergoing autologous Haematopoietic stem cell transplant. Br J Haematol 201(4):e37-e41, 2023. e-Pub 2023. PMID: 36916461.
2. Pasvolsky O, Gaballa MR, Milton DR, Masood A, Sami SS, Tanner MR, Bashir Q, Srour S, Saini N, Ramdial J, Nieto Y, Tang G, Lin P, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4;14): The MD Anderson Cancer Center Experience: Transplant in t(4;14) MM. Transplant Cell Ther 29(4):260.e1-260.e6, 2023. e-Pub 2023. PMID: 36646323.
3. Shank BR, Primeaux B, Yeung EK, Horowitz SB, Lee IY, Roccograndi L, Feng L, Kaufman GP, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Weber DM, Becnel MR, Thomas SK. Hyperfractionated Cyclophosphamide and Dexamethasone Alone or in Combination with Daratumumab and/or Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma: A Single-Center Retrospective Analysis. Clin Lymphoma Myeloma Leuk 23(4):279-290, 2023. e-Pub 2022. PMID: 36797154.
4. Qiu L, Nwogbo OV, Medeiros LJ, Thakral B, Li S, Xu J, You MJ, Wang W, Quesada AE, Ramos CB, McDonnell TJ, Thomas SK, Lin P. Lymphoplasmacytic Lymphoma with IgG or IgA Paraprotein: A Study of 29 Cases including Cases that Can Mimic Plasma Cell Neoplasms. Hum Pathol 130:47-57, 2022. e-Pub 2022. PMID: 36244464.
5. Mohan M, Becnel MR, Shah UA, Dong H, Gundarlapalli S, Peterson T, Orozco JS, Horowitz S, Chhabra S, Dhakal B, Thanendrarajan S, Radhakrishnan SV, Al Hadidi S, Tan C, Mailankody S, Hultcrantz M, Korde N, Hassoun H, Lesokhin AM, Thomas SK, Patel KK, Manasanch EE, Weber DM, Szabo A, Kaufman GP, Lee HC, Zangari M, van Rhee F, Usmani SZ, D'Souza A, Orlowski RZ, Schinke C. Clinical Efficacy of Sequencing CD38 targeting monoclonal antibodies in Relapsed Refractory Multiple Myeloma: A multi-institutional experience. Am J Hematol 97(7):E276-E280, 2022. e-Pub 2022. PMID: 35472167.
6. Afrough A, Pasvolsky O, Ma J, Srour S, Bashir Q, Saini N, Hosing C, Popat UR, Kebriaei P, Delgado R, Ullah MR, Murphy R, Manasanch EE, Lee HC, Kaufman GP, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Impact of Induction with VCD vs. VRD on the Outcome of Patients with Multiple Myeloma After an Autologous Hematopoietic Stem Cell Transplantation. Transplant Cell Ther 28(6):307.e1-307.e8, 2022. e-Pub 2022. PMID: 35331973.
7. Patel KK, Shah JJ, Feng L, Lee HC, Manasanch EM, Olsem J, Morphey A, Huo XJ, Thomas SK, Bashir Q, Qazilbash MH, Weber DM, Orlowski RZ. Safety and Efficacy of Combination Maintenance Therapy with Ixazomib and Lenalidomide in Post-transplant Myeloma Patients. Clin Cancer Res 28(7):1277-1284, 2022. e-Pub 2022. PMID: 34992070.
8. Gaballa MR, Ma J, Tanner MR, Al-Juhaishi T, Bashir Q, Srour SA, Saini NY, Ramdial JL, Nieto Y, Murphy R, Rezvani K, Tang G, Lee HC, Patel KK, Kaufman GP, Manasanch EE, Ullah MR, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Real-world long-term outcomes in multiple myeloma with VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance. Leuk Lymphoma 63(3):1-12, 2022. e-Pub 2021. PMID: 34686083.
9. Srour SA, Milton DR, Bashir Q, Nieto Y, Saini N, Daher M, Ramdial J, Im J, Hosing C, Delgado R, Manasanch E, Lee HC, Thomas S, Kaufman G, Patel K, Popat U, Weber D, Orlowski R, Shpall E, Champlin RE, Qazilbash MH. Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma. Haematologica 106(12):3211-3214, 2021. e-Pub 2021. PMID: 34407606.
10. Patel R, Ma J, Bashir Q, Delgado R, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Daher M, Mehta R, Srour S, Weber DM, Thomas SK, Lee HC, Patel KK, Orlowski RZ, Shpall ES, Champlin RE, Saini N, Qazilbash MH. Black multiple myeloma patients undergoing upfront autologous stem cell transplant have similar survival outcomes compared to Whites: A propensity-score matched analysis. Am J Hematol 96(12):E455-E457, 2021. e-Pub 2021. PMID: 34559916.
11. Kunacheewa C, Feng L, Manasanch EE, Bashir Q, Patel KK, Mehta R, Kaufman GP, Srour S, Saini N, Iyer SP, Thomas SK, Weber DM, Orlowski RZ, Qazilbash MH, Lee HC. Outcomes of lenalidomide retreatment with novel triplet regimens in patients with multiple myeloma progressing on lenalidomide-based maintenance therapy. Br J Haematol 193(3):e23-e26, 2021. e-Pub 2021. PMID: 33748943.
12. Manasanch EE, Berrios D, Fountain E, Claussen CM, Chuang T, Kaufman G, Amini B, Bashir Q, Nieto Y, Qazilbash M, Patel K, Thomas SK, Weber DM, Berkova Z, Toruner G, Lin P, Feng L, Lee HC, Orlowski RZ, Kunacheewa C. Gene expression profiling predicts relapse-free and overall survival in newly diagnosed myeloma patients treated with novel therapies. Br J Haematol 192(4):e115-e120, 2021. e-Pub 2021. PMID: 33486754.
13. Manasanch EE, Kunacheewa C, Claussen CM, Lee HC, Thomas SK, Gunther J, Pinnix CC, Dabaja BS, Amini B, Alexanian R, Orlowski RZ, Dong W, Feng L, Weber DM. Serum paraprotein persistence and size determine outcome in a cohort of patients with a modern definition of plasmacytoma with up to 19 years of follow up. Blood Cancer J 11(2):17, 2021. e-Pub 2021. PMID: 33563896.
14. Manasanch EE, Mulanovich V, Manzano JG, Gaeta MS, Becnel M, Kaufman GP, Lee HC, Amini B, Thomas SK, Iyer SP, Weber DM, Berkova Z, Flowers CR, Orlowski RZ, Patel KK. SARS-CoV-2 in multiple myeloma: initial observation and management. Leuk Lymphoma 61(11):2763-2766, 2020. e-Pub 2020. PMID: 33167721.
15. Saini N, Bashir Q, Milton DR, Tang G, Delgado R, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Mehta R, Srour S, Khouri IF, Weber DM, Thomas SK, Lee HC, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. Busulfan and melphalan conditioning is superior to melphalan alone in autologous stem cell transplantation for high-risk MM. Blood Adv 4(19):4834-4837, 2020. PMID: 33027527.
16. Thomas SK. Waldenström Macroglobulinemia - 2020 Update on Management and Future Directions. Clin Lymphoma Myeloma Leuk 20 Suppl 1:S39-S41, 2020. PMID: 32862863.
17. Elhammali A, Amini B, Ludmir EB, Gunther JR, Milgrom SA, Pinnix CC, Andraos T, Yoder A, Weber D, Orlowski R, Manasanch E, Patel K, Strati P, Nair R, Lee HC, Thomas S, Iyer S, Kaufmann G, Garg N, Dabaja BS. New paradigm for radiation in multiple myeloma: lower yet effective dose to avoid radiation toxicity. Haematologica 105(7):e355-e357, 2020. e-Pub 2020. PMID: 31919088.
18. Cordas Dos Santos DM, Saliba RM, Patel R, Bashir Q, Saini N, Hosing C, Kebriaei P, Khouri IF, Nieto Y, Popat U, Ahmed H, Lee HC, Manasanch EE, Patel KK,Thomas SK, Weber DM, Orlowski RZ, Champlin RE, Qazilbash MH. Age Is a Prognostic Factor for the Overall Survival of Patients with Multiple Myeloma Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 26(6):1077-1083, 2020. e-Pub 2019. PMID: 31786242.
19. Manasanch EE, Shah JJ, Lee HC, Weber DM, Thomas SK, Amini B, Olsem J, Crumpton B, Morphey A, Berkova Z, Feng L, Orlowski RZ. Phase I/Ib study of carfilzomib and panobinostat with or without dexamethasone in patients with relapsed/refractory multiple myeloma. Haematologica 105(5):e242-e245, 2020. e-Pub 2019. PMID: 31413094.
20. Kunacheewa C, Lee HC, Patel K, Thomas S, Amini B, Srour S, Bashir Q, Nieto Y, Qazilbash MH, Weber DM, Feng L, Orlowski RZ, Lin P, Manasanch EE. Minimal Residual Disease Negativity Does Not Overcome Poor Prognosis in High-Risk Multiple Myeloma: A Single-Center Retrospective Study. Clin Lymphoma Myeloma Leuk 20(5):e221-e238, 2020. e-Pub 2020. PMID: 32037287.
21. Owen RG, McCarthy H, Rule S, D'Sa S, Thomas SK, Tournilhac O, Forconi F, Kersten MJ, Zinzani PL, Iyengar S, Kothari J, Minnema MC, Kastritis E, Aurran-Schleinitz T, Cheson BD, Walter H, Greenwald D, Chen DY, Frigault MM, Hamdy A, Izumi R, Patel P, Wei H, Lee SK, Mittag D, Furman RR. Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study. Lancet Haematol 7(2):e112-e121, 2020. e-Pub 2019. PMID: 31866281.
22. Raab MS, Thomas SK, Ocio EM, Guenther A, Goh YT, Talpaz M, Hohmann N, Zhao S, Xiang F, Simon C, Vanasse KG, Kumar SK. The first-in-human study of the pan-PIM kinase inhibitor PIM447 in patients with relapsed and/or refractory multiple myeloma. Leukemia 33(12):2924-2933, 2019. e-Pub 2019. PMID: 31092894.
23. Lee HC, Shah JJ, Feng L, Morphey A, Johnson RJ, Wesson ET, Wang ML, Alexanian R, Thomas SK, Orlowski RZ, Weber DM. A phase I/II trial of the combination of lenalidomide, thalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Am J Hematol 94(12):E319-E322, 2019. e-Pub 2019. PMID: 31489991.
24. Varma A, Sui D, Milton DR, Tang G, Saini N, Hasan O, Mukherjee A, Joseph JJ, Bashir Q, Rondon G, Srour S, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Mehta R, Khouri IF, Ahmed H, Iyer S, Weber DM, Thomas SK, Manasanch E, Lee HC, Patel K, Ciurea SO, Shpall EJ, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched Analysis. Biol Blood Marrow Transplant. e-Pub 2019. PMID: 31881283.
25. Saini N, Ma J, Milton DR, Patel R, Varma A, Bashir Q, Delgado R, Mukherjee A, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Tang G, Mehta R, Srour S, Khouri IF, Iyer S, Weber DM, Thomas SK, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. Impact of Autologous Transplantation in Patients with Multiple Myeloma with t(11;14): A Propensity-Score Matched Analysis. Clin Cancer Res 25(22):6781-6787, 2019. e-Pub 2019. PMID: 31481508.
26. Lee HC, Shah JJ, Feng L, Manasanch EE, Lu R, Morphey A, Crumpton B, Patel KK, Wang ML, Alexanian R, Thomas SK, Weber DM, Orlowski RZ. A phase 1 study of filanesib, carfilzomib, and dexamethasone in patients with relapsed and/or refractory multiple myeloma. Blood Cancer J 9(10):80, 2019. e-Pub 2019. PMID: 31575851.
27. Tabchi S, Nair R, Kunacheewa C, Patel KK, Lee HC, Thomas SK, Amini B, Ahmed S, Mehta RS, Bashir Q, Qazilbash MH, Weber DM, Orlowski RZ, Alexanian R, Feng L, Manasanch EE. Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia. Clin Lymphoma Myeloma Leuk 19(9):560-569, 2019. e-Pub 2019. PMID: 31201134.
28. Saini NY, Patel RD, Varma A, Bashir Q, Delgado R, Rondon G, Mukherjee A, Popat U, Hosing C, Nieto Y, Kebriaei P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH, Patel KK. Outcomes of autologous stem cell transplantation in Waldenström's macroglobulinemia. Ann Hematol 98(9):2233-2235, 2019. e-Pub 2019. PMID: 31243571.
29. Elhammali A, Milgrom SA, Amini B, Gunther JR, Yoder A, Ludmir EB, Moon B, Weber DM, Thomas SK, Garg N, Manasanch EE, Patel KK, Orlowski RZ, Lee HC, Bird JE, Satcher R, Lin P, Pinnix CC, Dabaja BS. Postoperative Radiotherapy for Multiple Myeloma of Long Bones: Should the Entire Rod Be Treated?. Clin Lymphoma Myeloma Leuk 19(8):e465-e469, 2019. e-Pub 2019. PMID: 31133526.
30. Bashir Q, Thall PF, Milton DR, Fox PS, Kawedia JD, Kebriaei P, Shah N, Patel K, Andersson BS, Nieto YL, Valdez BC, Parmar S, Rondon G, Delgado R, Hosing C, Popat UR, Oran B, Ciurea SO, Lin P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Williams LA, Champlin RE, Qazilbash MH. Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial. Lancet Haematol 6(5):e266-e275, 2019. e-Pub 2019. PMID: 30910541.
31. Manasanch EE, Shah JJ, Lee HC, Weber DM, Thomas SK, Amini B, Feng L, Berkova Z, Hildebrandt M, Orlowski RZ. Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial. Lancet Haematol 5(12):e628-e640, 2018. PMID: 30501870.
32. Saini NY, Patel RD, Varma A, Bashir Q, Delgado R, Rondon G, Popat U, Hosing C, Nieto Y, Kebriaei P, Weber DM,Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH, Patel KK. Long-term durable efficacy of autologous stem cell transplantation in POEMS syndrome. Am J Hematol. e-Pub 2018. PMID: 30548467.
33. Afrough A, Saliba RM, Hamdi A, Hoeber DM, Thomas S, Orlowski RZ, Cnhar M, Varma A, Cornelison AM, Rondon G, Parmar S, Shah ND, Bashir Q, Hosing C, Popat U, Whamplin RE, Qazilbash MH. Impact of Induction Therapy on the Outcome of Immunoglobulin Light Chain Amyloidosis after Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 24(11):2197-2203, 2018. e-Pub 2018. PMID: 30016656.
34. Gowda L, Shah M, Badar I, Bashir Q, Shah N, Patel K, Kanagal-Shamanna R, Mehta R, Weber DM, Lee HC, Manasanch EE, Shah A, Thomas SK, Parmar S, Nieto Y, Orlowski RZ, Champlin R, Qazilbash MH. Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs. Bone Marrow Transplant. e-Pub 2018. PMID: 30446740.
35. Saini NY, Patel R, Varma A, Bashir Q, Delgado R, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Weber DM, Thomas SK, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. Melphalan-based autologous transplant in octogenarian multiple myeloma patients. Am J Hematol. e-Pub 2018. PMID: 30300461.
36. Chaudhry M, Steiner R, Claussen C, Patel K, Lee H, Weber D,Thomas S, Feng C, Amini B, Orlowski R, Feng L, Manasanch EE. Carfilzomib-based combination regimens are highly effective frontline therapies for multiple myeloma and Waldenström's macroglobulinemia. Leuk Lymphoma:1-7. e-Pub 2018. PMID: 30227761.
37. Ni H, Shirazi F, Baladandayuthapani V, Lin H, Kuiatse I, Wang H, Jones RJ, Berkova Z, Hitoshi Y, Ansell SM, Treon SP, Thomas SK, Lee HC, Wang Z, Davis RE, Orlowski RZ. Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191. Clin Cancer Res. e-Pub 2018. PMID: 30126942.
38. Hu B, Thall P, Milton DR, Sasaki K, Bashir Q, Shah N, Patel K, Popat U, Hosing C, Nieto Y, Lin P, Delgado R, Jorgensen J, Manasanch E, Weber D, Thomas S, Orlowski RZ, Champlin R, Qazilbash MH. High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes. Leuk Lymphoma:1-11. e-Pub 2018. PMID: 30032678.
39. Zhang X, Lee HC, Shirazi F, Baladandayuthapani V, Lin H, Kuiatse I, Wang H, Jones RJ, Berkova Z, Singh RK, Lu J, Qian Y, Raina K, Coleman KG, Crews CM, Li B, Wang H, Hailemichael Y, Thomas SK, Wang Z, Davis RE, Orlowski RZ. Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myeloma. Leukemia. e-Pub 2018. PMID: 29581547.
40. Mohyuddin GR, Faisal MS, Badar T, Shah N, Bashir Q, Patel KK, Hosing C, Popat UR, Rondon G, Delgado R, Shah JJ, Weber DM, Thomas SK , Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH. A case control study of syngeneic transplantation versus autologous transplantation for multiple myeloma: two decades of experiences from a single center. Leuk Lymphoma 59(2):1-4, 2018. e-Pub 2017. PMID: 28673185.
41. Thomas SK, Cha SC, Smith DL, Kim KH, Parshottam SR, Rao S, Popescu M, Lee VY, Neelapu SS, Kwak LW. Phase I study of an active immunotherapy for asymptomatic phase Lymphoplasmacytic lymphoma with DNA vaccines encoding antigen-chemokine fusion: study protocol. BMC Cancer 18(1):187, 2018. e-Pub 2018. PMID: 29439670.
42. Hao S, Lin P, Medeiros LJ, Fang L, Carballo-Zarate AA, Konoplev SN, Sargent RL, Weber DM, Thomas SK , Manasanch EE, Orlowski RZ, Lu X. Clinical implications of cytogenetic heterogeneity in multiple myeloma patients with TP53 deletion. Mod Pathol 30(10):1378-1386, 2017. e-Pub 2017. PMID: 28664940.
43. Mohyuddin GR, Faisal MS, Badar T, Shah N, Bashir Q, Patel KK, Hosing C, Popat UR, Rondon G, Delgado R, Shah JJ, Weber DM, Thomas SK , Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH. A case control study of syngeneic transplantation versus autologous transplantation for multiple myeloma: two decades of experiences from a single center. Leuk Lymphoma 1-4, 2017. PMID: 28673185.
44. Carballo-Zarate AA, Medeiros LJ, Fang L, Shah JJ, Weber DM, Thomas SK, Manasanch EE, Hao S, Shen Q, Orlowski RZ, Lin P, Lu X. Additional-structural-chromosomal aberrations are associated with inferior clinical outcome in patients with hyperdiploid multiple myeloma: a single-institution experience. Mod Pathol 30(6):843-853, 2017. e-Pub 2017. PMID: 28281554.
45. Baljevic M, Zaman S, Baladandayuthapani V, Lin YH, de Partovi CM, Berkova Z, Amini B, Thomas SK, Shah JJ, Weber DM, Fu M, Cleeland CS, Wang XS, Stellrecht CM, Davis RE, Gandhi V, Orlowski RZ. Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma. Ann Hematol 96(6):977-985, 2017. e-Pub 2017. PMID: 28337527.
46. Thuro BA, Sagiv O, Shinder R, Debnam JM, Ozgur O, Ng JD, Rootman D, Thomas SK, Esmaeli B. Clinical Presentation and Anatomical Location of Orbital Plasmacytomas. Ophthal Plast Reconstr Surg. e-Pub 2017. PMID: 28582371.
47. Bock F, Lu G, Srour SA, Gaballa S, Lin HY, Baladandayuthapani V, Honhar M, Stich M, Shah ND, Bashir Q, Patel K, Popat U, Hosing C, Korbling M, Delgado R, Rondon G, Shah JJ, Thomas SK, Manasanch EE, Isermann B, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 22(12):2159-2164, 2016. e-Pub 2016. PMID: 27638366.
48. Badar T, Cornelison AM, Shah ND, Bashir Q, Parmar S, Patel K, Hosing C, Popat U, Weber DM, Thomas SK, Shah JJ, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of Patients with Systemic Light chain (AL) Amyloidosis with Concurrent Renal and Cardiac Involvement. Eur J Haematol 97(4):342-7, 2016. e-Pub 2016. PMID: 26773409.
49. Cao X, Medeiros LJ, Xia Y, Wang X, Thomas SK, Loghavi S, Li X, Shah JJ, Gustafson SA, Weber DM, Miranda RN, Xu-Monette ZY, Orlowski RZ, Young KH. Clinicopathologic features and outcomes of lymphoplasmacytic lymphoma patients with monoclonal IgG or IgA paraprotein expression. Leuk Lymphoma 23(5):1-10, 2016. e-Pub 2015. PMID: 26421453.
50. Zhang XD, Baladandayuthapani V, Lin H, Mulligan G, Li B, Esseltine DL, Qi L, Xu J, Hunziker W, Barlogie B, Usmani SZ, Zhang Q, Crowley J, Hoering A, Shah JJ, Weber DM, Manasanch EE, Thomas SK, Li BZ, Wang HH, Zhang J, Kuiatse I, Tang JL, Wang H, He J, Yang J, Milan E, Cenci S, Ma WC, Wang ZQ, Davis RE, Yang L, Orlowski RZ. Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling. Cancer Cell 29(5):639-52, 2016. e-Pub 2016. PMID: 27132469.
51. Shah JJ, Feng L, Thomas SK, Berkova Z, Weber DM, Wang M, Qazilbash MH, Champlin RE, Mendoza TR, Cleeland C, Orlowski RZ. Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial. Blood Cancer J 6:e396, 2016. e-Pub 2016. PMID: 26871714.
52. Alfaraj WA, Cachia D, Tummala S, Thomas SK, Manasanch EE. Severe peripheral neuropathy following carfilzomib, rituximab, and dexamethasone for initial treatment of Waldenström's macroglobulinemia. Ann Hematol 95(2):347-8, 2016. e-Pub 2015. PMID: 26432713.
53. Jacobs RW, Saliba RM, Sasaki K, Farhan S, Armas A, Shah ND, Bashir Q, Qureshi S, Rondon G, Hosing C, Popat U, Parmar S, Shah JJ, Wang M, Weber DM, Thomas SK, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation. Clin Lymphoma Myeloma Leuk 16(1):36-42, 2016. e-Pub 2015. PMID: 26702475.
54. Mahale P, Thomas SK, Kyvernitakis A, Torres HA. Management of Multiple Myeloma Complicated by Hepatitis C Virus Reactivation: The Role of New Antiviral Therapy. Open Forum Infect Dis 3(1):ofv211, 2016. e-Pub 2015. PMID: 26885541.
55. Mendoza TR, Wang XS, Williams LA, Shi Q, Vichaya EG, Dougherty PM, Thomas SK, Yucel E, Bastida CC, Woodruff JF, Cleeland CS. Measuring Therapy-Induced Peripheral Neuropathy: Preliminary Development and Validation of the Treatment-Induced Neuropathy Assessment Scale. J Pain 16(10):1032-43, 2015. e-Pub 2015. PMID: 26210041.
56. Kuiatse I, Baladandayuthapani V, Lin HY, Thomas SK, Bjorklund CC, Weber DM, Wang M, Shah JJ, Zhang XD, Jones RJ, Ansell SM, Yang G, Treon SP, Orlowski RZ. Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy Against Waldenström's Macroglobulinemia. Clin Cancer Res 21(11):2538-45, 2015. e-Pub 2015. PMID: 25748087.
57. Cao X, Ye Q, Orlowski RZ, Wang X, Loghavi S, Tu M, Thomas SK, Shan J, Li S, Qazilbash M, Yin CC, Weber D, Miranda RN, Xu-Monette ZY, Medeiros LJ, Young KH. Waldenstrom macroglobulinemia with extramedullary involvement at initial diagnosis portends a poorer prognosis. J Hematol Oncol 8:74, 2015. e-Pub 2015. PMID: 26104577.
58. Kosturakis AK, He Z, Li Y, Boyette-Davis JA, Shah N, Thomas SK, Zhang H, Vichaya EG, Wang XS, Wendelschafer-Crabb G, Kennedy WR, Simone DA, Cleeland CS, Dougherty PM. Subclinical Peripheral Neuropathy in Patients With Multiple Myeloma Before Chemotherapy Is Correlated With Decreased Fingertip Innervation Density. J Clin Oncol 32(28):3156-62, 2014. e-Pub 2014. PMID: 25154818.
59. Dimopoulos MA, Kastritis E, Owen RG, Kyle RA, Landgren O, Morra E, Leleu X, García-Sanz R, Munshi N, Anderson KC, Terpos E, Ghobrial IM, Morel P, Maloney D, Rummel M, Leblond V, Advani RH, Gertz MA, Kyriakou C, Thomas SK, Barlogie B, Gregory SA, Kimby E, Merlini G, Treon SP. Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus. Blood 124(9):1404-11, 2014. e-Pub 2014. PMID: 25027391.
60. Patel K, Nusrat M, Shah N, Bashir Q, Parmar S, Shah J, Thomas S, Weber D, Orlowski RZ, Champlin R, Qazilbash MH. Durable responses with autologous hematopoietic SCT in patients with POEMS syndrome. Bone Marrow Transplant. Bone Marrow Transplant:465-6, 2014.
61. Bjorklund CC, Baladandayuthapani V, Lin HY, Jones RJ, Kuiatse I, Wang H, Yang J, Shah JJ, Thomas SK, Wang M, Weber DM, Orlowski RZ. Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications. Leukemia 28(2):373-83, 2014. e-Pub 2013. PMID: 23760401.
62. Thomas SK, Suvorov A, Noens L, Rukavitsin O, Fay J, Wu KL, Zimmerman TM, van de Velde H, Bandekar R, Puchalski TA, Qi M, Uhlar C, Samoylova OS. Evaluation of the QTc prolongation potential of a monoclonal antibody, siltuximab, in patients with monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, or low-volume multiple myeloma. Cancer Chemother Pharmacol 73(1):35-42, 2014. e-Pub 2013. PMID: 24149943.
63. Garcia MK, Cohen L, Guo Y, Zhou Y, You B, Chiang J, Orlowski RZ, Weber D, Shah J, Alexanian R, Thomas S, Romaguera J, Zhang L, Badillo M, Chen Y, Wei Q, Lee R, Delasalle K, Green V, Wang M. Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study. J Hematol Oncol 7:41, 2014. e-Pub 2014. PMID: 24886772.
64. Vichaya EG, Wang XS, Boyette-Davis JA, Mendoza TR, He Z, Thomas SK , Shah N, Williams LA, Cleeland CS, Dougherty PM. Subclinical pretreatment sensory deficits appear to predict the development of pain and numbness in patients with multiple myeloma undergoing chemotherapy. Cancer Chemother Pharmacol 71(6):1531-40, 2013. e-Pub 2013. PMID: 23543296.
65. Voorhees PM, Manges RF, Sonneveld P, Jagannath S, Somlo G, Krishnan A, Lentzsch S, Frank RC, Zweegman S, Wijermans PW, Orlowski RZ, Kranenburg B, Hall B, Casneuf T, Qin X, van de Velde H, Xie H, Thomas SK. A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma. Br J Haematol 161(3):357-66, 2013. e-Pub 2013. PMID: 23432640.
66. Wang M, Fowler N, Wagner-Bartak N, Feng L, Romaguera J, Neelapu SS, Hagemeister F, Fanale M, Oki Y, Pro B, Shah J, Thomas S, Younes A, Hosing C, Zhang L, Newberry KJ, Desai M, Cheng N, Badillo M, Bejarano M, Chen Y, Young KH, Champlin R, Kwak L, Fayad L. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia. e-Pub 2013. PMID: 23545991.
67. Jones D, Vichaya EG, Wang XS, Williams LA, Shah ND, Thomas SK, Johnson VE, Champlin RE, Cleeland CS, Mendoza TR. Validation of the M.S. Anderson sympton inventory multiple myeloma module. J Hematol Oncol 6:13, 2013. e-Pub 2013. PMID: 23384030.
68. Kuhn DJ, Berkova Z, Jones RJ, Woessner R, Bjorklund CC, Ma W, Davis RE, Lin P, Wang H, Madden TL, Wei C, Baladandayuthapani V, Wang M, Thomas SK, Shah JJ, Weber DM, Orlowski RZ. Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma. Blood 120(16):3260-70, 2012. e-Pub 2012. PMID: 22932796.
69. Mendoza TR, Koyyalagunta D, Burton AW, Thomas SK, Phan MH, Giralt SA, Shah JJ, Cleeland CS. Changes in pain and other symptoms in patients with painful multiple myeloma-related vertebral fracture treated with kyphoplasty or vertebroplasty. J Pain 13(6):564-70, 2012. e-Pub 2012. PMID: 22543044.
70. Thomas SK, Kwak LW. Lymphoma Vaccine Therapy: Next Steps After a Positive, Controlled Phase III Clinical Trial. Semin Oncol 39(3):253-62, 2012. PMID: 22595048.
71. Zheng Y, Yang J, Qian J, Zhang L, Lu Y, Li H, Lin H, Lan Y, Liu Z, He J, Hong S, Thomas S, Shah J, Baladandayuthapani V, Kwak LW, Yi Q. Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone. J Mol Med (Berl) 90(6):695-706, 2012. e-Pub 2011. PMID: 22207485.
72. Bashir Q, Khan H, Orlowski RZ, Amjad AI, Shah N, Parmar S, Wei W, Rondon G, Weber DM, Wang M, Thomas SK, Shah JJ, Qureshi SR, Dinh YT, Popat U, Anderlini P, Hosing C, Giralt S, Champlin RE, Qazilbash MH. Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma. Am J Hematol 87(3):272-6, 2012. e-Pub 2012. PMID: 22231283.
73. Bashir Q, Shah N, Parmar S, Wei W, Rondon G, Weber DM, Wang M, Orlowski RZ, Thomas SK, Shah J, Qureshi SR, Dinh YT, Popat U, Anderlini P, Hosing C, Giralt S, Champlin RE, Qazilbash MH. Feasibility of autologous hematopoietic stem cell transplant in patients aged 70 years with multiple myeloma. Leuk Lymphoma 53(1):118-22, 2012. e-Pub 2011. PMID: 21780997.
74. Reed V, Shah J, Medeiros LJ, Ha CS, Mazloom A, Weber DM, Arzu IY, Orlowski RZ, Thomas SK, Shihadeh F, Alexanian R, Dabaja BS. Solitary plasmacytomas: outcome and prognostic factors after definitive radiation therapy. Cancer 117(19):4468-74, 2011. e-Pub 2011. PMID: 21437886.
75. Hunsucker SA, Magarotto V, Kuhn DJ, Kornblau SM, Wang M, Weber DM, Thomas SK, Shah JJ, Voorhees PM, Xie H, Cornfeld M, Nemeth JA, Orlowski RZ. Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma. Br J Haematol 152(5):579-92, 2011. e-Pub 2011. PMID: 21241278.
76. Yang L, Wang H, Kornblau SM, Graber DA, Zhang N, Matthews JA, Wang M, Weber DM, Thomas SK, Shah JJ, Zhang L, Lu G, Zhao M, Muddasani R, Yoo SY, Baggerly KA, Orlowski RZ. Evidence of a role for the novel zinc-finger transcription factor ZKSCAN3 in modulating Cyclin D2 expression in multiple myeloma. Oncogene 30(11):1329-40, 2011. e-Pub 2010. PMID: 21057542.
77. Ma W, Wang M, Wang ZQ, Sun L, Graber D, Matthews J, Champlin R, Yi Q, Orlowski RZ, Kwak LW, Weber DM, Thomas SK, Shah J, Kornblau S, Davis RE. Effect of Long-term Storage in TRIzol on Microarray-Based Gene Expression Profiling. Cancer Epidemiol Biomarkers Prev 19(10):2445-52, 2010. e-Pub 2010. PMID: 20805315.
78. Wang M, Delasalle K, Feng L, Thomas S, Giralt S, Qazilbash M, Handy B, Lee JJ, Alexanian R. CR represents an early index of potential long survival in multiple myeloma. Bone Marrow Transplant 45(3):498-504, 2010. e-Pub 2009. PMID: 19633690.
79. Thomas SK, Richards TA, Weber DM. Novel agents for relapsed and/or refractory multiple myeloma. Cancer J 15(6):485-93, 2009. PMID: 20010168.
80. Popat U, Saliba R, Thandi R, Hosing C, Qazilbash M, Anderlini P, Shpall E, McMannis J, Körbling M, Alousi A, Andersson B, Nieto Y, Kebriaei P, Khouri I, de Lima M, Weber D, Thomas S, Wang M, Jones R, Champlin R, Giralt S. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow Transplant 15(6):713-723, 2009. e-Pub 2009. PMID: 19450756.
81. Thomas SK, Fossella FV, Liu D, Schaerer R, Tsao AS, Kies MS, Pisters KM, Blumenschein GR, Glisson BS, Lee JJ, Herbst RS, Zinner RG. Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with Gefitinib on an expanded access program. Clin Lung Cancer 7(5):326-331, 2006. PMID: 16640804.

Invited Articles

1. Thomas SK, Richards TA, Weber DM. Novel agents for relapsed and/or refractory multiple myeloma. Cancer 15(6):485-93, 2009.
2. Shah JJ, Orlowski RZ, Thomas SK. Role of combination bortezomib and pegylated liposomal doxorubicin in the management of relapsed and/or refractory multiple myeloma. Ther Clin Risk Manag 5(1):151-159, 2009. e-Pub 2009. PMID: 19436606.
3. Thomas S, Alexanian R. Current treatment strategies for multiple myeloma. Clin Lymphoma Myeloma 7 Suppl 4:S139-44, 2007. PMID: 17562251.
4. Thomas SK, Richards TA, Weber DM. Lenalidomide in multiple myeloma. Best Pract Res Clin Haematol 20(4)(4):717-735, 2007. PMID: 18070715.

Manuals, Teaching Aids, Other Teaching Publications

1. Thomas S. Multiple Myeloma: Questions and Answers. M.D. Anderson Cancer Center: Houston, 2005.

Abstracts

1. Chiu CY, Ahmed S, Thomas SK, Wang LS, Mustafayev K, Fayad LE, Wierda WG, Khawaja F, Torres HA. Hepatitis B virus reactivation in patients receiving Bruton tyrosine kinase inhibitors. Clinical Lymphoma Myeloma Leuk, 2023.
2. Trudel S, Cohen AD, Krishnan AY, Fonseca R, Spencer A, Berdeja JG, Lesokhin A, Forsberg PA, Laubach JP, Costa LJ, Rodriguez-Otero P, Kaedbey R, Richter J, Mateos M-V, Thomas SK, Wong C, Li M, Choeurng V, Vaze A, Samineni D, Sumiyoshi T, Cooper J and Harrison SJ. Cevostamab Monotherapy Continues to Show Clinically Meaningful Activity and Manageable Safety in Patients with Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study. Blood 138(653):157, 2021.
3. Tohidi-Esfahani I, Warden A, Malunis E, deNardis PL, Postek M, D'Sa S, Kersten MJ,Thomas SK, Palomba ML, Olszewski AJ, Guerin N, Scott C, and Trotman J. Global Waldenström’s Macroglobulinemia Patient-Derived Data Registry, Whimsical, Highlights Real-World Treatment Outcomes and COVID-19 Data. Blood 138(623):1343, 2021.
4. Treon SP, Buske C, Thomas SK, Castillo JJ, Branagan AR, Dimopoulos MA, Gavriatopoulou M, Cadavid D, Garzon FT, Tang W, Seyffert S, Garg V, Ali S, Taveras AG, Chen K and Matous JV. Preliminary Clinical Response Data from a Phase 1b Study of Mavorixafor in Combination with Ibrutinib in Patients with Waldenström’s Macroglobulinemia With MYD88 and CXCR4 Mutations. Blood 138(623):1343, 2021.
5. Bashir Q, Thall PF, Sui D, Ramdial JL, Srour SA, Mehta RS, Popat UR, Nieto Y, Saini N, Kebriaei P, Manasanch EE, Lee HC, Kaufman GP, Thomas SK, Patel KK, Orlowski RZ, Knape CG, Kawedia JD, Champlin RE, Shpall EJ, Liu X and Qazilbash MH. A Prospective Phase I/II Trial to Jointly Optimize the Administration Schedule and Dose of Melphalan for Injection (Evomela) As a Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma. Blood 138(731):3941, 2021.
6. Manasanch EE, Lee HC, Patel KK, Weber DM, Lee HJ, Thomas SK , Chen W, Oriabure On, Badillo M, Graham V, Lei FE, McCarthy MS, Orlowski RZ, Wang M. A Phase I/II Study of Pomalidomide and Dexamethasone with Growth Factor Support in Patients with Relapsed/Refractory Multiple Myeloma. Blood Journal 130(Suppl 1), 2017.
7. Thomas SK , Shah JJ, Lee HC, Manasanch EE, Weber DM, Patel KK, Feng LE, Amini BE, Morphey A, Crumpton BR, Phillips SA, Miller CA, Gonzalez MA, Orlowski RZ. Preliminary Results of a Phase II Study of Lenalidomide-Elotuzumab As Maintenance Therapy Post-Autologous Stem Cell Transplant in Patients with Multiple Myeloma. Blood Journal 130(Suppl 1), 2017.
8. Popescu M, Shah N, Bashir Q, Patel K, Shpall EJ, Weber DM, Thomas SK, Shah JJ, Robert Z. Orlowski RZ, Kerr N, Garfall Al. Randomized Phase II Trial of Combination Idiotype Vaccine and Anti-CD3/Anti-CD28 Costimulated Autologous T Cells in Patients with Multiple Myeloma Post-Autotransplantation. Blood 128(22), 2016.
9. Popat UR, Parmar S, Rondon G, Delgado R, Weber DM, Shah JJ, Thomas S, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH. A Case Control Study of Syngeneic Transplantation Versus Autologous Transplantation for Multiple Myeloma: Two Decades of Experience at MD Anderson. Blood 128(22), 2016.
10. Nooka AK, Wang M, Yee AJ, Thomas SK, O'Donnell EK, Shah JJ, Kaufman JL, Peterkin D. Final Results of a Phase 1/2a, Dose Escalation Study of Pvx-410 Multi-Peptide Cancer Vaccine in Patients with Smoldering Multiple Myeloma (SMM). Blood 128(22), 2016.
11. Hu B, Sasaki K, Bashir Q, Shah N, Patel KK, Popat UR, Hosing C, Nieto Y, Lin P, Delgado R, Jorgensen JL, Shah JJ, Manasanch EE, Weber DM, Thomas SK, Orlowski RZ, Champlin RE, Qazilbash MH. Depth of response post autologous hematopoietic stem cell transplantation (auto-HCT) to predict outcome in high risk multiple myeloma (MM). J Clin Oncol 34, 2016.
12. Shah JJ, Feng L, Thomas SK et al. Phase 1 Study of the Novel Kinesin Spindle Protein Inhibitor Filanesib + Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM). Blood 126(23), 2015.
13. Nooka AK, Wang M, Yee AJ, Thomas SK, O'Donnell EK, Shah JJ, Kaufman JL, Lonial S, Richardson PG, Raje NS. Updated Results of a Phase 1/2a, Dose Escalation Study of Pvx-410 Multi-Peptide Cancer Vaccine in Patients with Smoldering Multiple Myeloma (SMM). Blood 126(23):4246, 2015.
14. Shah JJ, Feng L, Weber D, Thomas SK, Wang M, Turturro F, Qazilbash MH, Shah N, Bashir Q, Popat UR, Manasanch EE, Munoz SC, Landry A, MendozaK, Nieto Y, Champlin RE, Orlowski RZ. Phase II Study of the Combination of Ixazomib with Lenalidomide As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma. Blood 126(23):3155, 2015.
15. Sasaki K, Shah N, Bashir Q, Hosing CM, Popat UR, Nieto Y, Parmar S, Shah JJ, Weber D, Weissinger D, Thomas SK, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of Patients with Light Chain Multiple Myeloma Compared to IgG/IgA Myeloma after Autologous Stem Cell Transplant. Blood 126(23):3194, 2015.
16. Claussen CM, Chuang T, Jatin Shah, Lee H, Shah N, Patel KK, Bashir Q, Parmar S, Thomas S, Qazilbash M, Davis RE, Neelapu SS, Weber D, Orlowski RZ, Feng L, Manasanch EE. Use of Gene Expression Profiling May Predict Clinical Outcomes in Newly Diagnosed Multiple Myeloma Patients in a Standard of Care Setting. Blood 126(23):5390, 2015.
17. Wang Y, Wagner-Bartak N, Zhou S, Fowler N, Dela Rosa ML, Zhao D, Romaguera JE, Neelapu SS, Hagemeister FB, Fanale MA, Oki Y, Shah JJ, Thomas SK, Hosing CM, Zhang L, Badillo M, Chen W, Cai Q, Zou D, Champlin RE, Fayad LE, Lee HJ, Michael Wang. Lenalidomide Plus Rituximab for Relapsed or Refractory Diffuse Large B-Cell, Follicular and Transformed Lymphoma: Final Data Analysis of a Phase 2 Trial. Blood 126(23):3969, 2015.
18. Dimopoulos MA, Kastritis E, Owen RG, Kyle RA, Landgren O, Morra E, Leleu X, Garcıa-Sanz R, Munshi N, Anderson KC, Terpos E, Ghobrial IM, Morel P, Maloney D, Rummel M, Leblond V, Advani RH, Gertz MA, Kyriakou C, Thomas SK, Barlogie B, Gregory SA, Kimby E, Merlini G, Treon SP. Treatment recommendations for patients with Waldenstrom¨ macroglobulinemia (WM) and related disorders: IWWM-7 consensus. Blood 124(21), 2014.
19. Ocio EM, Thomas SK, Günther A, Lebovic D, Kumar SK, Jakubowiak AJ, Song D, Ziang F, Hynds D, Vanase KG, Goh YT. Phase 1 Study Of The Novel Pan-Pim Kinase Inhibitor LGH447 In Patients With Relapsed/ Refractory Multiple Myeloma. Blood 122(21), 2013.
20. Bjorklund CC, Baladandayuthapani V, Lin HY, Jones RJ, Kuiatse I, Wang H, Yang J, Shah JJ, Thomas SK, Wang M, Weber DM, Orlowski RZ. Evidence of a Role for CD44 and Cell Adhesion in Mediating Resistance to Lenalidomide in Multiple Myeloma: Therapeutic Implications. Leukemia. e-Pub 2013. PMID: 23760401.
21. Treon SP, Tripsas CK, Meid K, Patterson C, Heffner LT, Eradat H, Gregory SA, Thomas SK, Advani RH, Baz R, Badros AZ, Matous J, Murphy TJ, Ghobrial IM. Prospective, Multicenter Study Of The Mtor Inhibitor Everolimus (RAD001) As Primary Therapy In Waldenstrom’s Macroglobulinemia. Blood 122(21), 2013.
22. Thomas SK, Haygood TM, Qazilbash MH, Melendez A, Galvis R, Delasalle KB, Feng L, Richards TA, Samaniego F, Wang L, Shah JJ, Orlowski RZ, Weber DM. A Phase II Trial Of Bortezomib-Rituximab Followed By Autologous Stem Cell Harvest (SCH) and Cladribine-Cyclophosphamide-Rituximab (2CdA-Cy-Rit) Consolidation As Primary Therapy Of Waldenström's Macroglobulinemia (WM). Blood 122(21), 2013.
23. Alagappan A, Shah R, Thomas SK, Weber DM, Wang M, Alexanian R, Orlowski RZ, Shah JJ. Feasibility and Activity Of Bortezomib-Based Therapy In Patients With Relapsed/Refractory Multiple Myeloma Previously Treated With Carfilzomib. Blood 122(21), 2013.
24. Shah, JJ, Baladandayuthapani V, Weber DM, Thomas SK, Alexanian R, Wang M, Qazilbash MH, Champlin RE, Shah N, Bashir Q, Popat UR, Nieto Y, Ahmed S, Parmar S, Orlowski RZ. Phase II Study Of The Combination Of MLN 9708 With Lenalidomide As Maintenance Therapy Post Autologous Stem Cell Transplant In Patients With Multiple Myeloma. Blood 122(21), 2013.
25. Kuhn DJ, Berkova Z, Jones RJ, Woessner R, Bjorklund CC, Ma W, Davis RE, Lin P, Wang H, Madden TL, Wei C, Baladandayuthapani V, Wang M, Thomas SK, Shah JJ, Weber DM, Orlowski RZ. Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma. Blood 120(21), 2012.
26. Vichaya EG, Wang S, Boyette-Davis JA, Thomas SK, Shah N, Mendoza TR, Williams LA, Cleeland CS, Dougherty PM. Baseline subclinical sensory deficits and the development of pain and numbness in patients with multiple myeloma (MM) being treated with chemotherapy. J Clin Oncol 30, 2012.
27. Thomas SK, Mendoza TR, Vichaya EG, Wang XS, Sailors MH, Williams LA, Dougherty PM, Cleeland CS. Validation of the chemotherapy-induced neuropathy assessment scale. J Clin Oncol 30, 2012.
28. Thomas SK. ISSMM and IPSSWM as Prognosticators in WM. Venice, Italy, 2010. 6th International Workshop on Waldenstrom's Macroglobulinemia Venice, 2010.
29. Popat U, Saliba R, Thandi R, Hosing C, Qazilbash M, Anderlini P, Shpall E, McMannis J, Korbling M, Alousi A, Andersson B, Nieto Y, Kebriaei P, Khouri I, Marcos D, Weber DM, Thomas S, Wang M, Jones R, Champlin R, Giralt S. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Blood 15(6):718-23, 2009. PMID: 19450756.
30. Shah N, Weber D, Orlowski R, Wang M, Thomas SK, Richards T, Giralt S, Qazilbash M, Alexanian R and Shah JJ. Role of autologous stem cell transplant after induction therapy with bortezomib-lenolidomide or bortezomib-thalidomide in newly diagnosed multiple myeloma patients. J Clin Oncol 27(Suppl):15S, 2009.
31. Voorhees PM, Manges RF, Somio G, Lentzsch S, Jagannath S, Sonneveld P, Frank RC, Zweegman S, Wijermans PW, Thomas S. A phase II multicenter study of CNTO 328, an anti-IL-6 monoclonal antibody, in patients (pts) with relapsed or refractory multiple myeloma (MM). J Clin Oncol 27(15s), 2009.
32. Delasalle KB, Wang L, Weber D, Giralt SA, Thomas S, Shah J, Handy B, Orlowski RZ, Alexanian R. Curability of Multiple Myeloma. Blood (ASH Annual Meeting Abstracts) 114:3864, 2009.
33. Thomas S, Feng L, Delasalle KB, Wang M, Shah JJ, Orlowski RZ, Alexanian R, Weber DM. Prognostic Factors for survival after 2-CdA-based therapy for symptomatic Waldenstrom Macroglobulinemia (WM) stratify patients into low- and high-risk groups. Blood (ASH Annual Meeting Abstracts) 114:1668, 2009.
34. Shah N, Weber DM, Wang M, Thomas S, Shah J, Giralt S, Alexanian R, Orlowski RZ, Qazilbash MH, and Avery T. Survival Disparities Between African-American and Caucasian Patients with Multiple Myeloma Are Blunted in the Era of Novel Therapeutics and Autologous Stem Cell Transplantation. Blood:1395, 2009.
35. Thomas S, Hosing C, Delasalle K, Gavino M, Popat U, Qazilbash M, Giralt S, Weber D, Alexanian R.. Success rates of autologous stem cell collection in patients with Waldenstrom Macroglobulinemia. 5th International Workshop on Waldenstrom's Macroglobulinemia Stockholm. Sweden 2008, 2008.

Book Chapters

1. Lee HC, Manasanch EE, Thomas SK et al. Multiple Myeloma and other Plasma Cell Dyscrasias. In: The M.D. Anderson Manual of Medical Oncology. McGraw Hill, 229-253, 2016.
2. Thomas S, Wang M, Weber D. Abnormal serum protein electrophoresis. In: Decision Making in Medicine, An Algorithmic Approach. Mosby, Inc: Philadelphia, 2010.
3. Thomas S, Richards T, Weber DM. Novel agents for previously untreated multiple myeloma. In: Multiple Myeloma. Informa Healthcare: New York, 2008.
4. Thomas S, Richards T, Weber DM.. Lenalidomide in relapsed or refractory multiple myeloma. In: Myeloma Myeloma Therapy: Pursuing the Plasma Cell (Contemporary Hematology). The Humana Press, Inc: Totowa, NJ, 2008.